De EUA en partners schrijven onder meer: ‘Innovative MedicinesJoint Technology Initiative (IMI) was launched in May 2007. Fromthe beginning, significant stakeholder groups have expressedconcerns about IMI’s intellectual property rights policy and itsfunding model.
These concerns have been repeated on several occasions and havebeen transmitted to the IMI Member States Group, the IMI JointUndertaking (JU) Governing Board and the European Commission.Participation in the first two calls has been well below potential,because many organisations – SMEs, research organisations anduniversities – have not participated fully as a result of concernsregarding the complex and potentially un-balanced IMI IP policy andunattractive funding model. The programme is unlikely to achieveits objectives if participation remains sub-optimal.’
U leest het gezamenlijke statement van de EUA, Duitse, Zweedse,Spaanse en Vlaamse instituten